New Delhi, February 27 Glenmark Pharmaceuticals announced on Friday that its US-based unit is preparing to introduce a generic sodium phosphate injection in the American market.
The Mumbai-based pharmaceutical company stated that its product is therapeutically equivalent to Hosira Inc.'s reference listed drug.
Glenmark will begin distributing the injection in the US market in April 2026, as stated in a regulatory filing.
According to IQVIA, sales data for the 12-month period ending December 2025 showed that the Sodium Phosphate Injection USP single-dose vials generated annual sales of approximately USD 66.8 million.
The company's shares were trading up 0.82% at Rs 2,144.50 apiece on the BSE.